The cardiothoracic surgeon breaks down Lilly's newly published phase 3 retatrutide results from the New England Journal of Medicine in a new video.
Recap by typeshit. Post by Facebook on Facebook.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
She points to work shown at ADA 2026 and published in Nature Communications suggesting semaglutide may improve epigenetic aging markers.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
Testers rated intake, pricing and support at each telehealth service. Fortune notes many also sell compounded GLP-1s the FDA hasn't approved.
Georgakis points out that omics work usually shows up in observational cohorts, and credits Novo for building it into trials and sharing the findings.
Loading…